How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

Hormone Replacement Therapy Market: Unveiling t...

Hormone Replacement Therapy (HRT) stands as a big ray of hope for individuals affected by the multifaceted challenges of hormonal imbalances. Defined as the administration of synthetic or natural h...

Feb 21, 2024

Pharma News for Novartis, Iovance, Certa, Innovent
FDA Approves Xolair for Food Allergies; FDA Accelerated Approval for Iovance’s AMTAGVI; Astellas and Kelonia Enter into Research and License Agreement; Fast Track Designation to Certa’s FT011; Innovent Announces Phase 3 Clinical Trial Updates for IBI311; Orphan Drug Designation to Cardiol’s Pericarditis Drug Candidate

FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Roche has announced that the FDA has approved Xolair® (omalizumab) to mitigate allergic responses, such as anaphylaxis, that may arise from accidental exposure to various foods in both adult and pediatric patie...

Find More
complement-3-glomerulopathy-treatment-therapies
Advancements in Complement 3 Glomerulopathy (C3G) Treatment: Exploring Upcoming Anti-Complements

Complement 3 glomerulopathy (C3G) is a form of glomerular disease where there’s a notable presence of C3 complement component deposits in the glomeruli. These deposits occur without significant amounts of immunoglobulin and without the deposition of C1q and C4. The buildup of C3, without much classical or lectin co...

Find More
crovalimab-for-pnh-treatment
Will Roche’s Crovalimab An Answer to AstraZeneca PNH Treatment Drugs?

China has become the first nation to approve Roche’s crovalimab, a paroxysmal nocturnal hemoglobinuria (PNH) treatment. Unlike AstraZeneca’s infused treatments Soliris and Ultomiris, crovalimab is administered subcutaneously. Developed by Roche’s subsidiary Chugai Pharmaceutical, crovalimab is a humanized complemen...

Find More

More Views & Analysis

Pharma News for GSK, Gilead, CSL, CymaBay
GSK Receives FDA Fast Track Designation for Bepirovirsen; Gilead to Acquire CymaBay Therapeutics; CSL Announces Top-line Results from the Phase III AEGIS-II Trial; Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment; CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar; Biogen Received European Commission Approval for SKYCLARYS

GSK Receives FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B GSK plc has revealed that the US Food and Drug Administration (FDA) has awarded Fast Track status to bepirovirsen, an experimental antisense oligonucleotide (ASO) designed to treat chronic hepatitis B (CHB). Fast Track designation ai...

Find More

glioma-vs-glioblastoma-therapeutics-space
Glioma vs. Glioblastoma Therapeutics Space: Unveiling the Battlefront

Glioma and glioblastoma are both types of brain tumors, but they differ significantly in their characteristics and prognosis. Glioma is a broad term that encompasses tumors originating from glial cells, which are supportive cells in the brain. These tumors can vary in grade and aggressiveness, with some growing slo...

Find More

dupixent-for-eosinophilic-esophagitis-treatment
Dupixent Breaks Ground: First and Only Eosinophilic Esophagitis Treatment for Pediatric Patients

Sanofi and Regeneron are prioritizing pediatric care, particularly in their recent progress with the potent anti-inflammatory drug, Dupixent. On January 25, 2024, the FDA approved Dupixent, an IL-4 receptor alpha antagonist, for the treatment of eosinophilic esophagitis (EoE) in children aged 1 to 11, weighing at l...

Find More

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...

Find More

Pharma News For Astellas, AnaMar, Biosyngen
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016

4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...

Find More

opportunities-and-challenges-for-cell-and-gene-therapies
Opportunities and Challenges for Cell and Gene Therapies

Gene therapy is an innovative medical approach that manipulates an individual’s genetic material to prevent or treat diseases. It primarily involves introducing, modifying, or substituting genes within a patient’s cells. The central objective of gene therapy is to rectify genetic abnormalities, insert missing genes...

Find More

Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skel.....

Find More

The EU market contains more than 55 biosimilars for around 15 oncology, autoimmune, diabetes, and fe.....

Find More

Neuroendocrine tumors (NET) are a rare kind neoplasm that arises from cells of the endocrine (hormon.....

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....

Find More

Digital therapies are evidence-based clinical approaches powered by software applications designed t.....

Find More